| Literature DB >> 33503843 |
Stéphane Fattori1,2, Laurent Gorvel1,2, Samuel Granjeaud3, Philippe Rochigneux1,2,4, Marie-Sarah Rouvière1,2, Amira Ben Amara1,2, Nicolas Boucherit1,2, Magali Paul1,2, Marie Mélanie Dauplat5, Jeanne Thomassin-Piana5, Maria Paciencia-Gros5, Morgan Avenin5, Jihane Pakradouni6, Julien Barrou7, Emmanuelle Charafe-Jauffret5,8,9, Gilles Houvenaeghel7,9, Eric Lambaudie7,9, François Bertucci4,10, Anthony Goncalves4,10, Carole Tarpin4, Jacques A Nunès1, Raynier Devillier1,2,9,11, Anne-Sophie Chretien1,2,9, Daniel Olive1,2,9.
Abstract
The rationale for therapeutic targeting of Vδ2+ γδ T cells in breast cancer is strongly supported by in vitro and murine preclinical investigations, characterizing them as potent breast tumor cell killers and source of Th1-related cytokines, backing cytotoxic αβ T cells. Nonetheless, insights regarding Vδ2+ γδ T cell phenotypic alterations in human breast cancers are still lacking. This paucity of information is partly due to the challenging scarcity of these cells in surgical specimens. αβ T cell phenotypic alterations occurring in the tumor bed are detectable in the periphery and correlate with adverse clinical outcomes. Thus, we sought to determine through an exploratory study whether Vδ2+ γδ T cells phenotypic changes can be detected within breast cancer patients' peripheral blood, along with association with tumor progression. By using mass cytometry, we quantified 130 immune variables from untreated breast cancer patients' peripheral blood. Supervised analyses and dimensionality reduction algorithms evidenced circulating Vδ2+ γδ T cell phenotypic alterations already established at diagnosis. Foremost, terminally differentiated Vδ2+ γδ T cells displaying phenotypes of exhausted senescent T cells associated with lymph node involvement. Thereby, our results support Vδ2+ γδ T cells implication in breast cancer pathogenesis and progression, besides shedding light on liquid biopsies to monitor surrogate markers of tumor-infiltrating Vδ2+ γδ T cell antitumor activity.Entities:
Keywords: between-group analysis; breast cancers; immune monitoring; liquid biopsy; mass cytometry; γδ T cells
Year: 2021 PMID: 33503843 PMCID: PMC7865589 DOI: 10.3390/cancers13030441
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639